Spinal Metastasis as the First Presentation of Lung Malignancy: Clinical Characteristics and Postoperative Survival

NCT ID: NCT07100444

Last Updated: 2025-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

139 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the clinical features and postoperative survival outcomes between patients with spinal metastasis as the initial manifestation of malignancy and those with spinal metastasis occurring after an established diagnosis of malignancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to compare the clinical features and postoperative survival outcomes between patients with spinal metastasis as the initial manifestation of malignancy and those with spinal metastasis occurring after an established diagnosis of malignancy. By analyzing and contrasting these two groups, we seek to identify any distinctive characteristics, prognostic factors, and potential implications for early detection and treatment strategies in patients with malignant spinal metastases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancers Bone Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spinal Metastasis as the First Presentation of Lung Malignancy

It refers to patients who first present with symptoms such as pain or spinal cord compression caused by spinal metastasis, leading to the initial detection of bone metastasis, and are subsequently diagnosed with lung cancer.

No interventions assigned to this group

lung cancer who subsequently developed spinal metastasis

It refers to patients with a history of treatment for primary lung cancer who subsequently developed spinal metastasis during the course of the disease.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years.
2. Pathologically or radiologically confirmed diagnosis of lung cancer with spinal metastasis.
3. Patients with spinal metastasis who underwent surgical intervention.
4. Adequate medical records and follow-up data available.

Exclusion Criteria

1. Patients with spinal metastasis originating from non-lung primary tumors.
2. Patients who did not receive surgical treatment for spinal metastasis.
3. Incomplete clinical data or lost to follow-up.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Guangdong Provincial People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yu Zhang, PhD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

lungfirstboneMetas

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.